1. Home
  2. Clinical Topics
  3. New treatment for advanced epithelioid sarcoma
Clinical TopicsDrugs and DevicesNewsOncologyOncology Resource CenterRare Diseases

New treatment for advanced epithelioid sarcoma

By: Lydia L. Kim, Digital Content Editor

The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with metastatic or advanced epithelioid sarcoma (AES).

AES is a rare sarcoma that affects the soft tissue in upper extremities. The approval of tazemetostat continues to highlight the FDA’s efforts in helping increase the quality of lives of patients who suffer from rare disorders.

Please read more about the approval here. And more about AES here.


Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts